drugset / Trial / NCT00391755

A Double-Blind Placebo-Controlled Trial of Rozerem in Migraine Headaches

NCT00391755

RandomizedParallel-groupDouble-blindTreatment

Summary

To study the effect of Rozerem, a high affinity MT1 and MT2, low affinity 5-HT2B receptor agonist used for insomnia, as a migraine prophylactic agent.

Timeline

Start
2006-10
Primary completion
2009-10
Completion
2009-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ramelteon Unknown 8 mg Oral

Indications